-
March 22, 2024Umecrine Cognition’s Phase 1b/2 study of golexanolone in Primary Biliary Cholangitis progresses to Part B following positive safety reviewSTOCKHOLM – March 22, 2024. Umecrine Cognition today announces the successful completion of the first part (Part A) of its ongoing clinical Phase...
-
March 18, 2024Umecrine Cognition will attend BIO-Europe Spring® 2024 in BarcelonaSTOCKHOLM – March 18, 2024. Umecrine Cognition today announces that the company will attend BIO-Europe Spring® in Barcelona, Spain. The meeting...
-
March 15, 2024Scientific review of golaxonolone’s therapeutic potential on symptoms arising from neuroinflammation published in Frontiers in PharmacologySTOCKHOLM – March 15, 2024. Umecrine Cognition today announces that the company has contributed to a review article outlining the scientific...
Subscribe
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.